title: 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma.
abstract: Colorectal adenocarcinoma is a common cause death cancer in the whole world. The aim of this study is to define the 111In-cetuximab as a diagnosis tracer of human colorectal adenocarcinoma. In this research, cell uptake, nano-SPECT/CT scintigraphy, autoradiography, biodistribution and immunohitochemical staining of EGF receptor were included. HCT-116 and HT-29 cell expressed a relatively high and moderate level of EGF receptor, respectively. The nano-SPECT/CT image of 111In-cetuximab showed tumor radiation uptake of subcutaneous HCT-116 xenograft tumor was higher than SW-620. Autoradiography image also showed that tumor of HCT-116 had high 111In-cetuximab uptake. Mice that bearing CT-26 in situ xenograft colorectal tumors showed similar high uptake in vivo and ex vivo through nano-SPECT/CT imaging at 72 hours. Metastatic HCT-116/Luc tumors demonstrated the highest uptake at 72 hours after the injection of 111In-cetuximab. Relatively, results of 111In-DTPA showed that metabolism through urinary system, especially in the kidney. The quantitative analysis of biodistribution showed count value of metastatic HCT-116/Luc tumors that treated with 111In-cetuximab had a significant difference (P < 0.05) compared with that treated with 111In-DTPA after injection 72 hours. Result of immunohistologic staining of EGF receptor also showed high EGF receptor expression and uptake in metastatic colorectal tumors. In summary, we suggested that 111In-cetuximab will be a potential tool for detecting EGF receptor expression in human metastatic colorectal carcinoma.
authors.affiliation: Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.|Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan.
authors.forename: Ying-Hsia
authors.initials: YH
authors.lastname: Shih
authors.affiliation: Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan.
authors.forename: Cheng-Liang
authors.initials: CL
authors.lastname: Peng
authors.affiliation: Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.
authors.forename: Shin-Yu
authors.initials: SY
authors.lastname: Lee
authors.affiliation: Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.|Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan.
authors.forename: Ping-Fang
authors.initials: PF
authors.lastname: Chiang
authors.affiliation: Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.|Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
authors.forename: Cheng-Jung
authors.initials: CJ
authors.lastname: Yao
authors.affiliation: Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan.
authors.forename: Wuu-Jyh
authors.initials: WJ
authors.lastname: Lin
authors.affiliation: Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan.|Institute of Radiological Science, Central University, Taichung, Taiwan.
authors.forename: Tsai-Yueh
authors.initials: TY
authors.lastname: Luo
authors.affiliation: Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan.|Department of Oncology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
authors.forename: Ming-Jium
authors.initials: MJ
authors.lastname: Shieh
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000000981:diagnostic imaging; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D001692:Biological Transport / Q000502:physiology; D045744:Cell Line, Tumor; D000068818:Cetuximab / Q000494:pharmacology*; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging*; D066246:ErbB Receptors / Q000378:metabolism*; D045325:HCT116 Cells; D019073:HT29 Cells; D064593:Heterografts; D006801:Humans; D007205:Indium Radioisotopes; D007668:Kidney / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D009368:Neoplasm Transplantation; D011859:Radiography; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab
keywords: EGF receptor; cetuximab; colorectal adenocarcinoma; nano-SPECT/CT